S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout

Avalo Therapeutics (AVTX) Stock Forecast, Price & News

$4.02
-0.13 (-3.13%)
(As of 06/9/2023 ET)
Compare
Today's Range
$4.01
$4.38
50-Day Range
$1.80
$4.15
52-Week Range
$1.41
$7.41
Volume
27,143 shs
Average Volume
48,266 shs
Market Capitalization
$53.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Avalo Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
285.6% Upside
$15.50 Price Target
Short Interest
Healthy
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$309,678 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.13) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

586th out of 988 stocks

Pharmaceutical Preparations Industry

272nd out of 480 stocks


AVTX stock logo

About Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Stock News Headlines

AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Reviewing Avalo Therapeutics (AVTX) and Its Rivals
See More Headlines

AVTX Price History

AVTX Company Calendar

Last Earnings
3/29/2023
Today
6/10/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+285.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,660,000.00
Net Margins
-170.36%
Pretax Margin
-170.20%

Debt

Sales & Book Value

Annual Sales
$18.05 million
Book Value
($1.16) per share

Miscellaneous

Free Float
7,208,000
Market Cap
$53.06 million
Optionable
Optionable
Beta
1.62

Key Executives

  • Dr. Garry A. Neil M.D. (Age 69)
    Chairman, Pres & CEO
    Comp: $601.9k
  • Mr. Christopher Ryan SullivanMr. Christopher Ryan Sullivan (Age 39)
    CFO & Head of Investor relations
    Comp: $466.94k
  • Dr. Solomon H. Snyder M.D. (Age 84)
    Founder and Chairman of Scientific Advisory Board
  • Dr. Barbara S. Slusher Ph.D. (Age 58)
    Founder and Member of Scientific Advisory Board
  • Dr. Lisa Hegg Ph.D.
    Sr. VP of Program Management, Corp. Infrastructure & Clinical Operations
  • Ms. Colleen Matkowski
    Sr. VP of Global Regulatory Affairs & Quality Assurance
  • Dr. Dino C. Miano Ph.D.
    Sr. VP of CMC & Technical Operations













AVTX Stock - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVTX shares.
View AVTX analyst ratings
or view top-rated stocks.

What is Avalo Therapeutics' stock price forecast for 2023?

1 brokers have issued 12 month target prices for Avalo Therapeutics' stock. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 285.6% from the stock's current price.
View analysts price targets for AVTX
or view top-rated stocks among Wall Street analysts.

How have AVTX shares performed in 2023?

Avalo Therapeutics' stock was trading at $5.0401 at the beginning of the year. Since then, AVTX stock has decreased by 20.2% and is now trading at $4.02.
View the best growth stocks for 2023 here
.

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AVTX earnings forecast
.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its earnings results on Wednesday, March, 29th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.52. The firm earned $0.90 million during the quarter, compared to analyst estimates of $5.20 million. Avalo Therapeutics had a negative trailing twelve-month return on equity of 950.78% and a negative net margin of 170.36%.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split before market open on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (33.44%), Great Point Partners LLC (3.60%), Alyeska Investment Group L.P. (3.03%), Braidwell LP (1.87%) and Monashee Investment Management LLC (0.45%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $4.02.

How much money does Avalo Therapeutics make?

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $53.06 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.

This page (NASDAQ:AVTX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -